Big Take

The Pharmaceutical Rivalry Behind the Weight-Loss Drug Boom

Jan 25, 2024
Pharmaceutical companies Eli Lilly and Novo Nordisk are in a century-long rivalry for dominance in the $80 billion weight-loss drug market. Eli Lilly's new drug, Zepbound, aims to help patients cut over 20% of their body weight and potentially turn Eli Lilly into the first trillion-dollar drug company. The podcast explores the contrasting strategies of the two companies in weight-loss drug development, the impact of innovation, and the ongoing competition in the market, including the potential entry of other drug makers.
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 4min
2
The Rivalry Between Eli Lilly and Novo Nordisk in Weight Loss Drug Development
04:16 • 5min
3
The Pharmaceutical Rivalry and the Impact of Innovation on Weight-Loss Drugs
09:42 • 5min
4
The Ongoing Competition in the Weight-Loss Drug Market
14:17 • 3min